Why the study?
Does sacubitril/valsartan reduce hospitalizations and the need for inotropic support in patients with advanced heart failure?
Does sacubitril/valsartan reduce hospitalizations and the need for inotropic support in patients with advanced heart failure?
This case series reports on the real-world use of sacubitril/valsartan in patients with advanced heart failure who are ineligible for advanced therapies.
Hypothesis-generating for sacubitril/valsartan in advanced HF ineligible for advanced therapies; prospective trials needed before adoption.
Patients with advanced heart failure (HF) experience a continuous decline in quality of life and have a very poor prognosis. Moreover, due to numerous comorbidities present in these patients, transplantation and left ventricular assist devices are usually impracticable in clinical practice. In this challenging setting, administration of inotropic agents may be the only possible therapy; however, this treatment requires frequent hospitalizations. Our hypothesis is that sacubitril/valsartan, given its marked efficacy and manageability, can be safely used in clinical practice in this setting, potentially reducing hospitalizations and the need for inotropic support. We report here our experience in a small series of patients with advanced HF treated with sacubitril/valsartan.
No takes yet. Share an insight, caveat, or question.
Vincenzi et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: